US Bancorp DE Has $507,000 Stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

US Bancorp DE grew its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 2,084.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,934 shares of the biopharmaceutical company's stock after purchasing an additional 31,426 shares during the period. US Bancorp DE's holdings in ACADIA Pharmaceuticals were worth $507,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Marshall Wace LLP grew its holdings in shares of ACADIA Pharmaceuticals by 431.1% during the 2nd quarter. Marshall Wace LLP now owns 2,774,353 shares of the biopharmaceutical company's stock valued at $45,083,000 after acquiring an additional 2,251,940 shares in the last quarter. Millennium Management LLC grew its stake in ACADIA Pharmaceuticals by 36.2% in the second quarter. Millennium Management LLC now owns 2,937,714 shares of the biopharmaceutical company's stock valued at $47,738,000 after purchasing an additional 781,070 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in ACADIA Pharmaceuticals in the 2nd quarter worth about $10,550,000. Fred Alger Management LLC raised its stake in shares of ACADIA Pharmaceuticals by 19.8% during the 2nd quarter. Fred Alger Management LLC now owns 2,704,439 shares of the biopharmaceutical company's stock worth $43,947,000 after purchasing an additional 446,875 shares in the last quarter. Finally, SG Americas Securities LLC lifted its holdings in shares of ACADIA Pharmaceuticals by 419.8% during the 3rd quarter. SG Americas Securities LLC now owns 517,124 shares of the biopharmaceutical company's stock valued at $7,953,000 after buying an additional 417,648 shares during the last quarter. Institutional investors and hedge funds own 96.71% of the company's stock.

Insider Activity at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, COO Brendan Teehan sold 9,534 shares of the business's stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $15.28, for a total value of $145,679.52. Following the completion of the sale, the chief operating officer now owns 52,177 shares of the company's stock, valued at $797,264.56. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other ACADIA Pharmaceuticals news, CFO Mark C. Schneyer sold 9,733 shares of the stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $15.28, for a total transaction of $148,720.24. Following the sale, the chief financial officer now directly owns 43,735 shares in the company, valued at $668,270.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Brendan Teehan sold 9,534 shares of the business's stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $15.28, for a total transaction of $145,679.52. Following the completion of the transaction, the chief operating officer now owns 52,177 shares of the company's stock, valued at $797,264.56. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 51,014 shares of company stock worth $779,494. Corporate insiders own 28.30% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on ACAD. StockNews.com upgraded ACADIA Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, September 13th. HC Wainwright reaffirmed a "buy" rating and set a $27.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. Cantor Fitzgerald lowered their target price on shares of ACADIA Pharmaceuticals from $37.00 to $28.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 7th. Royal Bank of Canada decreased their price target on shares of ACADIA Pharmaceuticals from $29.00 to $26.00 and set an "outperform" rating for the company in a report on Wednesday, August 7th. Finally, Needham & Company LLC reissued a "buy" rating and set a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. Six research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $25.56.

ACADIA Pharmaceuticals Trading Down 1.9 %

NASDAQ:ACAD traded down $0.34 on Tuesday, hitting $17.93. The company's stock had a trading volume of 989,651 shares, compared to its average volume of 1,685,862. ACADIA Pharmaceuticals Inc. has a one year low of $14.15 and a one year high of $32.59. The stock has a fifty day moving average of $15.48 and a two-hundred day moving average of $15.98. The firm has a market capitalization of $2.97 billion, a P/E ratio of 23.42 and a beta of 0.38.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.06. The company had revenue of $250.40 million for the quarter, compared to analyst estimates of $248.83 million. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 27.29%. The company's revenue was up 18.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.40) earnings per share. As a group, sell-side analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.51 EPS for the current year.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.